Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on McKesson (MCK – Research Report), Biogen (BIIB – ...

The recent funding marks the first investment of U.S. pharma giant Merck Sharp & Dohme (MSD) in a health tech startup in Asia Pacific. (MSD is the brand that Merck uses to operate outside the U.S ...

Making acquisitions is one potential back-up plan. Merck bought biotech group Acceleron Pharma for $11.5bn in 2021 and autoimmune disease specialist Prometheus Biosciences for $10.8bn in 2023.

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Germany’s Merck MRK1.45%increase; green up pointing triangle KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics SWTX 7.53%increase; green up pointing ...